AMPLIA THERAPEUTICS LIMITED (ATX)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

ATX

ATX - AMPLIA THERAPEUTICS LIMITED

FNArena Sector : NONE
Year End: March
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Debt/EBITDA: -0.03
Index:

0

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.145

25 Aug
2026

-0.005

OPEN

$0.15

-3.33%

HIGH

$0.16

4,338,430

LOW

$0.15

TARGET
$0.42 189.7% upside
FNARENA'S MARKET CONSENSUS FORECASTS
ATX: 1
Title FY25
Actual		 FY26
Actual		 FY27
Forecast		 FY28
Forecast
EPS (cps) xxx - 1.6 - 2.3 xxx
DPS (cps) xxx 0.0 N/A xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2026 FactSet UK Limited. All rights reserved
Title 202120222023202420252026
EPS Basic xxxxxxxxxxxxxxx-1.6
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx0.0 M
Book Value Per Share xxxxxxxxxxxxxxx7.7
Net Operating Cash Flow xxxxxxxxxxxxxxx-8.7 M
Net Profit Margin xxxxxxxxxxxxxxx-

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202120222023202420252026
Return on Capital Employed xxxxxxxxxxxxxxx-25.48 %
Return on Invested Capital xxxxxxxxxxxxxxx-25.37 %
Return on Assets xxxxxxxxxxxxxxx-23.94 %
Return on Equity xxxxxxxxxxxxxxx-25.48 %
Return on Total Capital xxxxxxxxxxxxxxx-43.32 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-8.8 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202120222023202420252026
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx0 M
Total Debt xxxxxxxxxxxxxxx0 M
Goodwill - Gross xxxxxxxxxxxxxxx-
Cash & Equivalents - Generic xxxxxxxxxxxxxxx28 M
Price To Book Value xxxxxxxxxxxxxxx3.05

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202120222023202420252026
Capex xxxxxxxxxxxxxxx0.0 M
Capex % of Sales xxxxxxxxxxxxxxx-
Cost of Goods Sold xxxxxxxxxxxxxxx0 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx13 M
Research & Development xxxxxxxxxxxxxxx9 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

1
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Bell Potter

05/08/2026

1

Speculative Buy

$0.42

189.66%

Amplia Therapeutics has signed a clinical trial collaboration and supply agreement with Eli Lilly. It will commence a phase 1b/2b trial in non-small cell lung cancer that will combine its FAK inhibitor narmafotinib with the Eli Lilly KRAS G12C inhibitor called olomorasib.

The trial should start in late 2026 across Australian and US sites. Bell Potter assesses the announcement provides credibility and validation for the company's drug. Speculative Buy rating retained along with a $0.42 target.

FORECAST
Bell Potter forecasts a full year FY27 EPS of minus -2.30 cents.
Bell Potter forecasts a full year FY28 EPS of minus -0.70 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

0

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY
Access Extra Coverage Research History >

ATX STOCK CHART

FNArena News on ATX

1
Next Week At A Glance – 18-22 May 2026

May 15 2026 - Weekly Reports
2
Dr Boreham’s Crucible: Amplia Therapeutics

Jun 05 2024 - Small Caps